Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 42 clinical trials
Neoadjuvant mFOLFOXIRI Plus Bevacizumab With Selective Radiotherapy in Patients With High-Risk Locally Advanced Rectal Cancer

Neadajuvant chemotherpay (NACT) alone has been proposed instead of preoperative chemoradiotherapy (CRT) with the aim of elimination of potential micrometastasis as early as possible while avoiding the adverse effects of radiotherapy, without jeopardizing local control.

primary tumor
colon cancer
colorectal cancer
adjuvant therapy
mri pelvis
  • 0 views
  • 19 Feb, 2024
Nedaplatin Versus Cisplatin in Treatment for Nasopharyngeal Carcinoma

To compare the effectiveness and toxicity of nedaplatin versus cisplatin in induction chemotherapy combined with concurrent chemoradiotherapy for locoregionally advanced nasopharyngeal carcinoma.

cisplatin
nasopharyngeal carcinoma
docetaxel
cancer
carcinoma
  • 0 views
  • 19 Feb, 2024
Radical Radiotherapy and Chemotherapy Combined With Maintenance Chemotherapy in the Treatment of Stage N3 NPC

This study is a randomized, phase II, prospective, multicenter clinical trial to evaluate the efficacy and safety of radical chemoradiotherapy plus oral capecitabine/teggio for 1 year in patients with N3.

alt/ast
nasopharyngeal biopsy
nasopharyngeal carcinoma
carcinoma
chemoradiotherapy
  • 0 views
  • 19 Feb, 2024
Altered Tumor Oxygenation by Metformin a Potential Step in Overcoming Radiotherapy Resistance in LACC

This study is a randomized, phase II, open label study in patients with LACC where patients are randomized to standard cisplatin-based chemoradiotherapy +/- Metformin. Metformin will be started one week prior to the start of chemoradiotherapy, and will be continued throughout the entire radiation treatment.

cisplatin
hypoxia
serum pregnancy test
diabetes
neutrophil count
  • 0 views
  • 19 Feb, 2024
Inductive Camrelizumab and Apatinib for Patients With Locally Advanced and Resectable Oral Squamous Cell Carcinoma

The innovation of this study is the combination of immune checkpoint inhibitor, Camrelizumab, and targeted drug against VEGFR, Apatinib, as an inductive therapy to treat the patients with locally advanced OSCC, followed with radical surgery and post-operative radiotherapy/chemoradiotherapy, the major pathologic response and safety will be evaluated as the primary …

vascular endothelial growth factor
hypoxia
lymph node metastases
squamous cell carcinoma of the head and neck
angiogenesis
  • 0 views
  • 19 Feb, 2024
Microbiome and Rectal Cancer

The purpose of our study is to determine if an association exists between the microbiome of those with rectal adenocarcinoma who are complete pathologic responders and those who have a partial or no response to neoadjuvant therapy.

rectal carcinoma
adjuvant therapy
cancer
adenocarcinoma
neoadjuvant therapy
  • 0 views
  • 19 Feb, 2024
Pembrolizumab Plus Paclitaxel Cisplatin Followed by Surgery for Locally Advanced ESCC

The purpose of this study is to observe and evaluate the efficacy and safety of pembrolizumab plus paclitaxel, cisplatin followed by Da Vinci robot radical surgery for locally advanced esophageal squamous cell carcinoma.

cisplatin
pembrolizumab injection
serum pregnancy test
pembrolizumab
squamous cell carcinoma of esophagus
  • 0 views
  • 19 Feb, 2024
Neoadjuvant Chemotherapy and Transoral Robotic Surgery for Oropharyngeal Cancer.

The objective of this trial is to study the efficacy of treatment of human papilloma virus (HPV) related oropharyngeal cancer with chemotherapy followed by Transoral Robotic Surgery (TORS) as definitive treatment. Current treatment of oropharyngeal cancer are chemo-radiotherapy. There is significant lifelong side effects associated with this approach related to …

primary tumor
oropharyngeal
absolute neutrophil count
neutrophil count
squamous cell carcinoma
  • 0 views
  • 19 Feb, 2024
Restrictive Use of Dexamethasone in Glioblastoma

The administration of steroids, most commonly dexamethasone (DEX), has established as standard of care during treatment of glioblastoma (GBM) and is widely used during the entire course of the disease including pre- and postoperative management, chemo- and radiotherapy. The primary purpose is to reduce tumor-associated vasogenic edema and to prevent …

glioblastoma multiforme
immunosuppression
neurologic symptoms
dexamethasone
  • 0 views
  • 19 Feb, 2024
Radiotherapy Plus Nimotuzumab or Cisplatin in Nasopharyngeal Carcinoma

This is a phase III randomized clinical trial of definitive radiotherapy plus EGFR blocker nimotuzumab versus radiotherapy plus cisplatin(CCRT) for nasopharyngeal carcinoma (NPC) patients with favorable response to induction chemotheray(IC), determining whether radiotherapy combined with nimotuzumab was non-inferior to CCRT and may provide new evidence for individualized comprehensive treatment of …

cisplatin
nasopharyngeal carcinoma
egfr blocker
EGFR
nimotuzumab
  • 0 views
  • 19 Feb, 2024